Wire · opportunities
Bluejay Diagnostics (BJDX) ties director's options to FDA device clearance
◆ Sectors
Diagnostics
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 18 August 2026 · Fusion42 review
Bluejay Diagnostics granted director Wurth Douglas Clark 100,000 stock options exercisable only upon FDA clearance of their Symphony IL-6 point-of-care testing device, aligning executive incentives with regulatory approval milestones.
This Wire brief sits within Fusion42's coverage of Diagnostics.
◆ ◆ The Wire takeaway
You face a hard regulatory milestone linking executive rewards to FDA approval that signals high dependence on successful device clearance. Align your regulatory and compliance strategy immediately as this approval is now central to company progress.
◆ Coverage
1 source · 18 Aug 2026
◆ Related on Wire
◆ Topics
Diagnosticsstock-optionsfda-approvalmedical-deviceexecutive-incentives